Oak Thistle LLC Makes New Investment in Cencora, Inc. (NYSE:COR)

Oak Thistle LLC purchased a new position in Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,077 shares of the company’s stock, valued at approximately $262,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Park Place Capital Corp purchased a new stake in shares of Cencora in the first quarter worth approximately $46,000. Silvia Mccoll Wealth Management LLC purchased a new stake in shares of Cencora in the first quarter worth approximately $211,000. Claro Advisors LLC purchased a new stake in shares of Cencora during the first quarter valued at approximately $278,000. Diversified Trust Co purchased a new stake in shares of Cencora during the first quarter valued at approximately $11,714,000. Finally, Oak Asset Management LLC purchased a new stake in shares of Cencora during the first quarter valued at approximately $1,104,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of a number of research analyst reports. Citigroup increased their price target on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird increased their price target on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Finally, SVB Leerink reaffirmed an “outperform” rating and set a $275.00 price target on shares of Cencora in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $235.30.

Insider Transactions at Cencora

In other news, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $223.86, for a total value of $419,513.64. Following the completion of the transaction, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at $2,973,756.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Gina Clark sold 1,874 shares of Cencora stock in a transaction on Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the completion of the sale, the executive vice president now owns 13,284 shares of the company’s stock, valued at $2,973,756.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dermot Mark Durcan acquired 500 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were acquired at an average cost of $218.58 per share, with a total value of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at approximately $4,781,656.08. The disclosure for this purchase can be found here. Insiders sold 1,956,675 shares of company stock valued at $422,352,056 over the last three months. Company insiders own 15.80% of the company’s stock.

Cencora Stock Performance

NYSE:COR traded down $1.72 during trading hours on Monday, reaching $223.58. The stock had a trading volume of 1,723,139 shares, compared to its average volume of 1,409,780. Cencora, Inc. has a 12-month low of $171.65 and a 12-month high of $246.75. The stock has a 50 day simple moving average of $228.85 and a 200 day simple moving average of $228.32. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The stock has a market cap of $44.59 billion, a P/E ratio of 24.46, a price-to-earnings-growth ratio of 1.57 and a beta of 0.45.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. During the same period last year, the company earned $3.50 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, research analysts forecast that Cencora, Inc. will post 13.44 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date was Thursday, May 9th. Cencora’s payout ratio is currently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.